

## PRESS RELEASE

### Immunocore wins Large Business of the Year at the 2018 Vale4Business Awards

(Oxford, UK and Philadelphia, USA, 21 May 2018) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, is pleased to note that the Company was the winner of the 2018 Vale4Business (V4B) Award for Large Business of the Year.



*The Immunocore team receive their award from Simon Bassett of Royds Withy King (far left) and speaker Graham Bell*

The V4B Awards aim to bring together the achievements of businesses in the area; recognising, rewarding and promoting our local success stories.

Immunocore joined a prestigious list of winners at this year's awards, including Oxford Space Systems and CIS Ltd, at the awards ceremony at the Williams F1 Conference Centre in Grove.

**Andrew Hotchkiss, Chief Executive Officer of Immunocore, said:** "We are delighted to have been presented with this award, which reflects the great progress we have made in growing our business but also developing our ImmTAC (Immune mobilising monoclonal TCRs Against Cancer) technology. We're particularly pleased to have been chosen among such strong competition in this region, which is such a great hub for dynamic businesses like Immunocore. The unique combination of factors which have helped nurture so many businesses in the Oxford region have played a key role in Immunocore's success and we're proud to be a standard-bearer for the area.

"I would like to thank the rest of the team at Immunocore for their invaluable hard work, commitment and support."

**Simon Bassett, lead partner from Oxfordshire based law firm and lead sponsors, Royds Withy King, said:**  
“Our firm has been a long-time supporter of the Vale4Business team and we were delighted to present Immunocore with Large Business of the Year Award.

“As a Sunday Times Top 100 firm with pride in supporting our communities and helping businesses to get ahead, we were impressed by Immunocore’s growth, their commitment to engaging their employees and to public engagement and outreach with their many STEM ambassadors.”

- Ends -

**For more information, please contact:**

**Immunocore**

Andrew Hotchkiss, Chief Executive Officer

E: [info@immunocore.com](mailto:info@immunocore.com)

Follow on Twitter: [@Immunocore](https://twitter.com/Immunocore)

**Consilium Strategic Communications**

Mary-Jane Elliott/Jessica Hodgson/Chris Welsh/Laura Thornton

T: +44 (0)203 709 5700

E: [Immunocore@consilium-comms.com](mailto:Immunocore@consilium-comms.com)

Follow on Twitter: [@ConsiliumHC](https://twitter.com/ConsiliumHC)

**Notes for editors**

**About Immunocore**

Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. The Company’s primary therapeutic focus is oncology and it also has programs in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programs in development and the lead program, IMCgp100, has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with an office outside Philadelphia, USA. The Company is privately held by a broad international investor base. For more information, please visit [www.immunocore.com](http://www.immunocore.com).